Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-11-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
独立董事提名人声明（三）
Board/Management Information Classification · 100% confidence The document is a public statement from the board of directors nominating an independent director candidate for the company's board. It contains detailed declarations about the nominee's qualifications, compliance with regulatory requirements, and independence criteria. There are no financial statements, earnings data, or report attachments. The content is focused on board/management information, specifically about a nomination for a board position. The document length is 3667 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Board/Management Information (MANG).
2019-11-07 Chinese
独立董事提名人声明（一）
Board/Management Information Classification · 100% confidence The document is a public statement from the board of directors nominating an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with regulatory requirements, and independence criteria. There are no financial statements, earnings data, or report attachments. The content focuses on board/management information, specifically the nomination of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is not an announcement of a report publication, so it is not RPA or RNS.
2019-11-07 Chinese
独立董事关于第二届董事会第三十七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the 37th meeting of the second board of directors of Betta Pharmaceuticals Co., Ltd. It discusses the nomination and election of non-independent and independent directors for the third board, their qualifications, and the proposed remuneration for independent directors. The content focuses on board and management changes and related governance matters. There is no financial data, earnings information, or report publication announcement. The document is not a full annual report, audit report, or earnings release. It is clearly related to board/management information, specifically about board elections and director nominations.
2019-11-07 Chinese
独立董事提名人声明（二）
Board/Management Information Classification · 100% confidence The document is a formal public statement from the board of directors of a company (贝达药业股份有限公司) nominating an individual (汪炜) as an independent director candidate. It includes detailed declarations about the nominee's qualifications, compliance with various regulatory requirements, and independence criteria. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management changes, specifically the nomination of a new independent director. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 3780 characters, which is consistent with a detailed announcement rather than a full report.
2019-11-07 Chinese
中国国际金融股份有限公司关于公司部分首次公开发行限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from China International Capital Corporation Limited regarding the unlocking and circulation of restricted shares of Betta Pharmaceuticals Co., Ltd. after its initial public offering (IPO) and listing on the Shenzhen Stock Exchange Growth Enterprise Market (GEM). It includes information about the IPO approval, shareholding structure, shareholders' commitments, share unlocking schedule, and compliance with relevant regulations. The document is not a financial report, earnings release, or management discussion, but rather a formal verification and compliance opinion related to share circulation post-IPO. This type of document is typically classified as a Regulatory Filing (RNS) because it is a regulatory compliance disclosure that does not fit into other specific categories such as capital updates or director dealings. The document length is 8486 characters, which is substantive and contains detailed regulatory content, not just an announcement or a brief notice.
2019-11-05 Chinese
首次公开发行前已发行股份上市流通提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the lifting of restrictions on previously issued shares before the company's initial public offering (IPO). It includes information about the number of shares becoming tradable, the shareholders involved, their commitments, and compliance with regulatory requirements. The document references regulatory approvals and compliance with stock exchange rules but does not contain financial statements or performance data. It is focused on the unlocking and circulation of shares, which is a capital structure event related to share liquidity and shareholder commitments. This fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings.
2019-11-05 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.